TORPEDO trial (17.5 months follow-up) | • 25% relative improvement in CVD risk factor screening • No significant difference in prescribing rates of recommended medicines for people at high CVD risk • High CVD risk individuals not prescribed optimal recommended treatment at baseline, intervention was associated with 33% relative improvement in prescribing rates |
Post-trial phase (18 months follow-up) | • Plateauing of improvement in screening of CVD risk factors • Ongoing improvement in prescribing of recommended medicines in both the intervention and usual care arm |